<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36950">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078921</url>
  </required_header>
  <id_info>
    <org_study_id>03/077/11</org_study_id>
    <nct_id>NCT02078921</nct_id>
  </id_info>
  <brief_title>The Effects of Inorganic Nitrate on Cardiac Muscle in Angina</brief_title>
  <official_title>The Effects of Inorganic Nitrate on Cardiac Muscle: Physiology, Pharmacology and Therapeutic Potential in Patients Suffering From Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aberdeen</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that interventions which modestly increase blood nitrite_
      improve skeletal muscle function on exercise while sparing oxygen, and have been also shown
      to open up the blood flow during periods of oxygen deprivation. Inorganic nitrate in the
      diet is absorbed into the bloodstream, concentrated and reduced by bacteria in the mouth to
      nitrite, which is then absorbed into the bloodstream. .

      The purpose of this study is to look at the effects of oral inorganic nitrate
      supplementation on clinical markers of heart ischaemia and the frequency of angina.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to 1mm ST depression</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is to assess whether oral nitrate treatment increase the time to 1mm ST depression on a modified Bruce protocol exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of chest pain</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to onset of chest pain on a modified Bruce protocol exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TDI systolic peak velocity</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Tissue Doppler Imaging (TDI) systolic peak velocity in ischaemic wall segments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina frequency</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Angina frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GTN use frequency</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>GTN use frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire Score</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified Seattle Angina Questionnaire Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrate/Nitrite</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurements of Nitrate and Nitrite in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Stable Angina</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inorganic Nitrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrate</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 and over with chronic stable angina (â‰¥2 months duration).

        Inclusion Criteria Following screening visit:

          -  A positive exercise ECG (1mmSTD at J+0.08 seconds) on a modified Bruce protocol
             treadmill exercise test.

          -  A positive dobutamine stress echocardiogram,

          -  and/or a positive myocardial perfusion scan (MPI),

          -  and/or a positive coronary angiogram.

        Exclusion Criteria:

          -  Unable to do exercise test

          -  Women of child bearing potential

          -  If of a racial origin at risk of glucose-6-phosphate dehydrogenase (G6PD) deficiency,
             G6PD will be excluded prior to inclusion in the study

          -  Resting STD&gt;=1mm

          -  NYHA 3 or 4 HF or LVEF&lt;45%

          -  Myocardial infarction or revascularisation within the last two months

          -  Left bundle branch block (LBBB)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiovascular Research facility, University of Aberdeen</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Frenneaux</last_name>
      <phone>01224 559573</phone>
    </contact>
    <investigator>
      <last_name>Michael Frenneaux, MB BS,MD,FRCP,FRACP,FACC,F</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
